U.S. markets closed

Onconova Therapeutics, Inc. (ONTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
4.9700-0.0600 (-1.19%)
At close: 4:00PM EDT
4.9600 -0.01 (-0.20%)
After hours: 07:53PM EDT

Onconova Therapeutics, Inc.

375 Pheasant Run
Newtown, PA 18940
United States
267 759 3680

Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Dr. Steven M. FruchtmanCEO, Pres & Director865.44kN/A1951
Mr. Mark Patrick Guerin CPAChief Financial Officer512.19kN/A1969
Mr. Abraham N. Oler J.D., M.B.A., Esq., CFASr. VP of Corp. Devel. & Gen. CounselN/AN/A1976
Dr. Mark Stephen GelderChief Medical OfficerN/AN/A1957
Dr. Ramesh KumarAdvisorN/AN/A1956
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Its novel proprietary multi-kinase inhibitor ON 123300 to target CDK4/6 and other tyrosine kinases. The company's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. In addition, it is involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.

Corporate Governance

Onconova Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.